Attenuated protein kinase C activity and translocation in Alzheimer's disease brain
- PMID: 7936052
- DOI: 10.1016/0197-4580(94)90023-x
Attenuated protein kinase C activity and translocation in Alzheimer's disease brain
Abstract
Protein kinase C (PKC) activity and its redistribution were determined in postmortem Alzheimer's disease (AD) and age-matched control brains. Cytosolic and membrane-associated PKC activities were lower in frontal and temporal cortices and hippocampi of AD brains. Increased concentrations of phosphatidyl-L-serine, Ca2+ or phorbol 12-myristate, 13-acetate only weakly increased enzyme activity in AD tissues. Redistribution of cytosolic PKC to the membranous fraction was elicited in control brain slices by 162 nM PMA in the presence of K+ (65 mM). This redistribution of the enzyme was markedly reduced in AD brain slices. In contrast, the immunoreactivity of the alpha- and gamma-PKC isozymes were elevated in cortical tissue from AD subjects. No changes were noted in beta-PKC immunoreactivity. These results suggest that the reduced PKC activity and the attenuated translocation of the enzyme in AD brain tissue may be attributed to down regulation of PKC or to alteration in PKC protein. The increase in PKC immunoreactivity may be a reflection of an altered susceptibility to proteolysis or a compensatory response secondary to the loss in enzyme activity.
Similar articles
-
Lithium treatment inhibits protein kinase C translocation in rat brain cortex.Psychopharmacology (Berl). 2001 Oct;158(1):80-6. doi: 10.1007/s002130100834. Psychopharmacology (Berl). 2001. PMID: 11685387
-
Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease.Neurology. 1993 Jul;43(7):1407-13. doi: 10.1212/wnl.43.7.1407. Neurology. 1993. PMID: 8327146
-
Characterization and differential distribution of the three major human protein kinase C isozymes (PKC alpha, PKC beta, and PKC gamma) of the central nervous system in normal and Alzheimer's disease brains.Lab Invest. 1991 Jan;64(1):35-44. Lab Invest. 1991. PMID: 1990207
-
Protein kinase C pharmacology: perspectives on therapeutic potentials as antidementic and cognitive agents.Recent Pat CNS Drug Discov. 2006 Jun;1(2):147-56. doi: 10.2174/157488906777452721. Recent Pat CNS Drug Discov. 2006. PMID: 18221200 Review.
-
Age-related alteration of PKC, a key enzyme in memory processes: physiological and pathological examples.Mol Neurobiol. 1998 Feb;16(1):49-62. doi: 10.1007/BF02740602. Mol Neurobiol. 1998. PMID: 9554701 Review.
Cited by
-
Bryostatin-1 vs. TPPB: dose-dependent APP processing and PKC-α, -δ, and -ε isoform activation in SH-SY5Y neuronal cells.J Mol Neurosci. 2012 Sep;48(1):234-44. doi: 10.1007/s12031-012-9816-3. Epub 2012 Jun 15. J Mol Neurosci. 2012. PMID: 22700373 Free PMC article.
-
Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease.Front Mol Neurosci. 2017 Sep 15;10:294. doi: 10.3389/fnmol.2017.00294. eCollection 2017. Front Mol Neurosci. 2017. PMID: 28966576 Free PMC article. Review.
-
Task demands dissociate the effects of muscarinic M1 receptor blockade and protein kinase C inhibition on attentional performance in rats.J Psychopharmacol. 2012 Aug;26(8):1143-50. doi: 10.1177/0269881111415732. Epub 2011 Sep 2. J Psychopharmacol. 2012. PMID: 21890584 Free PMC article.
-
Elevated CSF GAP-43 in Mild Cognitive Impairment Linked to Cognitive Impairment Through Increased Amyloid-β Accumulation, with a Shift to Reduced Amyloid-β Accumulation in Alzheimer's Disease.J Mol Neurosci. 2025 Mar 20;75(2):39. doi: 10.1007/s12031-025-02333-8. J Mol Neurosci. 2025. PMID: 40111590
-
Biomarkers of Alzheimer's disease: from central nervous system to periphery?Int J Alzheimers Dis. 2010 Dec 20;2011:342980. doi: 10.4061/2011/342980. Int J Alzheimers Dis. 2010. PMID: 21197431 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous